Thousands of cancer cases could be prevented with more breast removal surgeries
It can also be offered to women who are deemed to be high risk of the disease to prevent them from getting it in the first place.
A study has found that if more women were given preventative mastectomies, then about 6,500 cases of breast cancer could be prevented each year.
Risk-reducing mastectomies (RRM) are currently only offered to women with the BRCA1, BRCA2, PALB2 genes, experts said.
But the new analysis suggests that some women with other genes linked to a higher risk of breast cancer – including ATM, CHEK2, RAD51C, RAD51D – who may also be at higher risk due to a number of other factors may benefit from RRM if they are assessed as having a high risk of disease.
These other factors can include a family history of breast cancer, the number of children they have had, whether or not they breast fed and mammogram density.
Women in the UK have an 11% chance of developing breast cancer across their lifetime.
Medics can calculate a woman's risk of breast cancer using tools which combine the effect of various risk factors.
This is your breast check reminder!
Learn the signs and symptoms of breast cancer.https://t.co/7zXDHWex5B pic.twitter.com/f5vHQx576r
— Breast Cancer Now (@BreastCancerNow) May 6, 2025
Researchers from Queen Mary University of London and the London School of Hygiene and Tropical Medicine (LSHTM) found that if health officials could identify all women aged 30 to 55 who have a 35% or higher risk of breast cancer, and they all went on to have RRM, then an estimated 6,538 breast cancer cases could be prevented in the UK each year.
This is the equivalent of around 11% of the 59,000 women in the UK who are diagnosed with breast cancer each year.
The academics point out that women who have one of the other genes linked to breast cancer, who may be at high risk of disease, could potentially be found by a mechanism called 'cascade testing' – where genetic tests are offered to family members of women who have been found to have these different genes linked to breast cancer.
The economic evaluation study, published in the journal JAMA Oncology, concludes: 'Undergoing RRM appears cost-effective for women at 30-55 years with a lifetime BC-risk 35% (or more).
'The results could have significant clinical implications to expand access to RRM beyond BRCA1/BRCA2/PALB2 pathogenic variant carriers.'
Corresponding author on the paper, Professor Ranjit Manchanda, professor of gynaecological oncology at Queen Mary and consultant gynaecological oncologist, said: 'We for the first time define the risk at which we should offer RRM.
'Our results could have significant clinical implications to expand access to mastectomy beyond those patients with known genetic susceptibility in high penetrance genes- BRCA1/ BRCA2/ PALB2 – who are traditionally offered this.
'This could potentially prevent can potentially prevent (around) 6500 breast cancer cases annually in UK women.
'We recommend that more research is carried out to evaluate the acceptability, uptake, and long-term outcomes of RRM among this group'.
Dr Rosa Legood, associate professor in health economics at LSHTM, added: 'Undergoing RRM is cost-effective for women (aged) 30 to 55-years with a lifetime breast cancer risk of 35% or more.
'These results can support additional management options for personalised breast cancer risk prediction enabling more women at increased risk to access prevention.'
Women deemed to be at high risk of breast cancer can also be offered regular screening and medication.
Louise Grimsdell, Breast Cancer Now senior clinical nurse specialist, said: 'While this modelling provides valuable insights into the cost-effectiveness of risk-reducing mastectomy for women with a high risk of developing breast cancer, each individual must be offered all risk-management options that are suitable for them.
'Choosing to have risk-reducing surgery is a complex and deeply personal decision that comes with emotional and physical implications.
'So, it's vital women can consider all their options, including screening and risk-reducing medications, and are supported by their clinician to make an informed decision that's right for them.
'It's also crucial that the unacceptably long waits that far too many women who chose risk-reducing surgery are facing are urgently tackled.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mirror
a day ago
- Daily Mirror
'My sister thought lumps under her arms were swollen glands - she died on Sunday'
The Cushing family were shocked when dad Jeffery was diagnosed with breast cancer. But to their horror sisters Shelley, Andrea and Jemma were then also told they had the condition A mum has died from breast cancer after she and her two sisters inherited the BRCA2 gene mutation from their father. Jeffery Cushing was diagnosed with breast cancer after it was spotted on scans he got for unrelated bowel polyps. Tests revealed he had the gene which increases the risk of developing certain cancers. Tests revealed all of his daughters - Shelley Raymond, 46, Andrea Waterman, 51, and Jemma Cushing, 41, - not only had the mutation but all had already developed breast cancer. Shelley and Andrea - who had no symptoms - underwent double mastectomies and hysterectomies. After surgery, they were declared cancer free and are now on a five-year preventative course of tamoxifen, an estrogen-regulating medication. It comes after the NHS warns mouth symptom could be life-shortening disease. But Jemma's tests revealed her breast cancer had already spread to her spinal cord and brain. She'd previously dismissed lumps under her arms as swollen glands. The mum-of-five from Croydon died on July 27. Her devastated family are raising awareness of breast cancer in men - and urging anyone to never dismiss a lump. Shelley, an NHS administrator, from Croydon, Surrey, said: "My older sister Andrea and I had no symptoms – ours were quite deep in the boob. "But my little sister Jemma - hers was quite advanced at that point. She'd noticed some lumps under the arm but she presumed they were glands and didn't get it checked." She added: "Jemma's greatest concern was not for herself, but for her children, who are now facing the unimaginable: a future without their mum. Don't ignore a lump, don't think it's a gland, always check. You just never know going forward." Jeffery's children were shocked when he was diagnosed with breast cancer in 2019. A test for polyps on his bowel revealed they were harmless - but that he had breast cancer. The retired optician's assistant, who died at 72 in 2022 from a heart attack, only noticed lumps after doctors pointed them out, and he had them removed via a lumpectomy in 2019. Despite finding out he had the BRCA2 gene Shelley said the test "didn't feel urgent at the time". But Shelley decided she should get checked out in April 2021 and after testing positive her sisters followed suit. Their brother, James Cushing, 39, tested negative. Shelley and Andrea, a stay-at-home mum, were both diagnosed with early-stage breast cancer and had double mastectomies and hysterectomies in autumn 2021. "We were fast tracked for our surgeries," Shelley said. "It was quite traumatic. I've had issues with the implants so I've had four surgeries since. The diagnosis was such a shock. It turns out a couple of my older sister's kids have the gene and have to get surgery." Jemma was tested in autumn 2021 and found out she had stage three cancer. She had several lumps in both her boobs, including a 10cm lump in the lymph nodes under her arm. She had to undergo a double mastectomy, a hysterectomy, and nine months of intense chemotherapy, but in December 2023 she discovered the cancer had spread to her spine. "Just after Christmas, she had a call from her oncologist on December 27 and they said something had shown up in the scan because she had pains in her back," said Shelley. "She had terminal cancer in the back. She underwent more chemo to lengthen her life, delaying the inevitable. They didn't say how long we were looking at with her. "The cancer travelled up her spine to her brain." She died on July 27. "My sister was very strong," said Shelley. "She fought so hard, she was tough cookie." Jemma's four oldest children - 24, 20, 17 and 14 - "understood what's going on" with Jemma's diagnosis but her youngest, seven, "was a little bit unsure". "She kept saying her mum's a bit like a zombie and obviously that's really distressing for everybody," Shelley said. Shelley is now raising money for Jemma's children.
Daily Record
4 days ago
- Daily Record
How GPs can help ensure at-home cervical cancer tests are actually used
DIY smear tests are set to be sent to women from January in a bid to increase the number of people getting cervical screenings. Cancer is a cruel disease that does not discriminate and affects not only the patient but also their loved ones. Around six women in Scotland are diagnosed with cervical cancer every week, according to Public Health Scotland. Cervical screening is the best protection against cervical cancer and at-home kits will be offered to women who have rarely or have never attended theirs from January. There are fears that these DIY cervical cancer tests won't be used as much as hoped. But a study has suggested that the uptake is likely to be better if the kits are offered by a GP during a routine appointment. The upcoming tests, which can be performed at home, look for the human papillomavirus (HPV). This is the virus which is linked to the majority of cases of cervical cancer. So how can GPs help ensure at-home cervical cancer tests are actually used? A new study from Queen Mary University of London and King's College London examined the best ways women can be approached about performing the tests themselves at home by looking at 13 GP surgeries in west London. They found that under-screened women were more likely to take up the offer of a self-sample test if they were approached when they were visiting a GP for another reason. Fewer tests were returned when under-screened women were sent a test in the post, or were sent a letter inviting them to get a self-sampling kit. "The uptake of self-sampling was by far the highest among women who were opportunistically offered kits in primary care," the researchers wrote in the journal eClinicalMedicine. But the researchers said that more work was needed to ensure women who took up the offer returned their sample. They suggested that text or phone reminders "could be valuable". Of 449 women opportunistically offered a self-sample kit, 74 per cent accepted the offer and 52 per cent returned a sample within six months. Meanwhile, 198 of the 1,616 women sent a kit in the post (12%) and 76 of the 1,587 women sent a letter inviting them to order a kit (5%) returned a self-sample within six months. Join the Daily Record WhatsApp community! Get the latest news sent straight to your messages by joining our WhatsApp community today. You'll receive daily updates on breaking news as well as the top headlines across Scotland. No one will be able to see who is signed up and no one can send messages except the Daily Record team. All you have to do is click here if you're on mobile, select 'Join Community' and you're in! If you're on a desktop, simply scan the QR code above with your phone and click 'Join Community'. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. To leave our community click on the name at the top of your screen and choose 'exit group'. If you're curious, you can read our Privacy Notice. Professor Peter Sasieni from Queen Mary University of London, said offering a self-sample kit in person "was the most effective method of encouraging women to complete their cervical cancer screening tests." However, a "combination of approaches may be best for enabling more women to participate in cervical screening". The NHS offers cervical screening tests - also known as smear tests - to all women aged 25-64 every three years. But many people do not take up the offer, with a number citing a lack of time, discomfort or embarrassment. Data published by the NHS last November showed five million women are not up to date with routine check-ups.
South Wales Guardian
4 days ago
- South Wales Guardian
DIY cervical cancer tests most likely to be used if offered by GPs
From January next year, at-home kits will be offered to women who have rarely or have never attended their cervical screening. The tests, which can be performed at home, look for the human papillomavirus (HPV) – the virus which is linked to the majority of cases of cervical cancer. A new study examined the most effective ways women can be approached about performing the tests themselves at home. Researchers from Queen Mary University of London and King's College London performed a study across 13 GP surgeries in west London. They found that under-screened women were more likely to take up the offer of a self-sample test if they were 'opportunistically' approached when they were visiting a GP for another reason. Fewer tests were returned when under-screened women were sent a test in the post, or were sent a letter inviting them to get a self-sampling kit. Women who haven't come forward for cervical screening will be offered self-sampling kits. As part of the 10 Year Health Plan, we're tackling the barriers that keep some women away from potentially lifesaving screenings. Learn more: — Department of Health and Social Care (@DHSCgovuk) June 24, 2025 Of 449 women opportunistically offered a self-sample kit, 333 (74%) accepted the offer and 234 (52%) returned a sample within six months. Meanwhile, 198 of the 1,616 women sent a kit in the post (12%) and 76 of the 1,587 women sent a letter inviting them to order a kit (5%) returned a self-sample within six months. 'We showed that the uptake of self-sampling was by far the highest among women who were opportunistically offered kits in primary care,' the researchers wrote in the journal eClinicalMedicine. But the researchers said that more work was needed to ensure women who took up the offer returned their sample. 'Substantial numbers accepted (an opportunistic offer) or ordered (sent a letter) a kit but did not return a sample and over a quarter of those whose self-sample was HPV positive did not follow through with a clinician sample,' the authors added. They suggested that text or phone reminders 'could be valuable'. Senior researcher, Professor Peter Sasieni from Queen Mary University of London, said: 'Our study showed that offering a self-sample kit in person was the most effective method of encouraging women to complete their cervical cancer screening tests. But he said that a 'combination of approaches may be best for enabling more women to participate in cervical screening'. The NHS offers cervical screening tests – previously known as smear tests – to all women aged 25-64 every three years. But many people do not take up the offer, with a number citing a lack of time, discomfort or embarrassment. Data published by the NHS last November showed five million women are not up to date with routine check-ups.
